GlobalData has released its medical devices report, “MediPoint: Drug-Eluting Balloons APAC Analysis and Market Forecasts”. The report is an essential source of information and analysis on the drug-eluting balloons (DEB) market in Asia-Pacific (APAC). The report provides in-depth insight into the use of DEB for coronary and peripheral applications in the lower extremity including in-stent restenosis, bifurcation lesions, small vessel disease, femoropopliteal artery and below-the-knee lesions, chronic total occlusions, acute myocardial infarction and lesions in diabetics.

The DEB market in three APAC countries including Japan, China and India was assessed to identify and determine whether the current unmet needs are addressed, understand the challenges of DEB angioplasty and evaluate the current and future adoption of DEB for select coronary and peripheral indications. The APAC sales expectations are discussed through careful analysis of adoption patterns of using these DEB.

Clients can use this report to better understand the scope of this technology and for strategic planning to explore opportunities in this dynamic market. The report also provides insights into the competitive landscape, the marketed and pipeline DEB products, the current and emerging players and comparative market analysis of different types of interventional techniques used to treat coronary and peripheral artery disease. This report is built using data and information sourced from secondary sources and primary research interviews and survey with leading Interventional Cardiologists and Interventional Radiologists, with in-house analysis conducted by GlobalData’s team of industry experts.

Scope

• An overview of coronary artery disease and peripheral artery disease in the lower extremity, which includes epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines and modalities.

 

• Annualized total drug-eluting balloon market revenue by type of disease, annual cost of disease and drug-eluting balloons adoption pattern and procedure data in APAC from 2010-2012 and forecast for seven years to 2019.

 

• Key topics covered include strategic competitor assessment, market characterization, identification of unmet needs, reimbursement and regulatory considerations, evaluating market access in the three APAC countries covered in the report, and implications of the drug-eluting balloon market.

 

• Pipeline analysis: comprehensive data split across different stages of development, emerging trends and DEB designs in development, including investigation of DEB coating technology, antiproliferative agent used, balloon and catheter design and durability.

 

• Analysis of the current and future market competition in the APAC drug-eluting balloon market. Insightful review of the key industry drivers, opportunities, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

 

Reasons to buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

 

• Develop business strategies by understanding the trends shaping and driving the DEB market in APAC.

 

• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the APAC DEB market in the future.

 

• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

 

• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

 

• Track device sales in the APAC DEB market by disease and indication from 2010-2019.

 

• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

 

Table of Contents

 

1 Table of Contents 8

1.1 List of Tables 17

1.2 List of Figures 23

 

2 Introduction 26

2.1 Catalyst 27

 

3 Disease Overview 29

3.1 Overview 29

3.1.1 Coronary Artery Disease 29

3.1.2 Peripheral Artery Disease 29

3.2 Anatomy and Physiology 30

3.2.1 Coronary Arteries 30

3.2.2 Peripheral Arteries of the Lower Extremity 31

3.3 Pathophysiology 33

3.3.1 Coronary Artery Disease 33

3.3.2 Peripheral Artery Disease 34

3.4 Clinical Presentation 35

3.4.1 Symptoms 35

3.4.2 Risk Factors 38

3.4.3 Disease Classification 39

3.4.4 Diagnosis 41

3.4.5 Clinical Outcomes 44

3.5 Epidemiology 77

3.5.1 Coronary Artery Disease 77

3.5.2 Peripheral Artery Disease 80

3.6 Economic Impact of Coronary and Peripheral Artery Disease 83

3.6.1 Cost of Coronary Artery Disease 83

3.6.2 Cost of Peripheral Artery Disease 84

 

4 Competitive Assessment 85

4.1 Overview 85

4.2 Product Profiles by Company 87

4.2.1 Aachen Resonance 88

4.2.2 B. Braun 90

4.2.3 Biotronik 96

4.2.4 Blue Medical 99

4.2.5 Cardionovum 106

4.2.6 C.R. Bard 112

4.2.7 Concept Medical Research 118

4.2.8 Cook Medical 122

4.2.9 Eurocor 124

4.2.10 Medrad (Bayer Healthcare) 138

4.2.11 Medtronic 141

4.2.12 Minvasys 149

 

5 Unmet Needs 152

5.1 Need for Better Clinical Outcomes in Specific Lesions 152

5.1.1 Chronic Total Occlusions 152

5.1.2 Small-Vessel Coronary Lesions 153

5.1.3 Long Lesions 153

5.1.4 Heavily-Calcified and Uncrossable/Undilatable Lesions 154

5.1.5 Bifurcation Lesions 154

5.2 Need for Better Revascularization of the Femoropopliteal Artery 155

5.3 Difficulty in Treating the Infrapopliteal Artery 157

5.4 Eliminating Mechanisms of Failure with Balloon Angioplasty 158

5.5 Addressing Challenges of Stenting 160

5.5.1 Risk of Post-Procedural Complications 160

5.5.2 In-Stent Restenosis 161

5.5.3 Stent-In-Stent Procedures 163

5.5.4 Prolonged Dual Antiplatelet Therapy 164

5.5.5 Lack of Homogenous Drug Distribution 165

5.5.6 Delayed Healing 165

5.5.7 Stent Fracture 166

5.5.8 Negative Vessel Remodeling 167

5.5.9 Long-Term Vessel Patency 167

5.6 Need for Effective Therapy for Specific Patient Populations 168

5.7 Lack of Clinical Data 169

5.8 Addressing the Complications of Bypass Surgery 169

5.9 Need to Improve Medical Therapy 170

5.10 Comparative Studies on Exercise Therapy for PAD 171

 

6 Pipeline Products 172

6.1 Overview 172

6.2 Pipeline by Stage of Development 173

6.3 Pipeline Product Profiles 175

6.3.1 NF-?B Decoy Oligo DEB 175

6.3.2 Drug-Coated AngioSculpt 177

6.3.3 BioPath 180

6.3.4 BioStream 181

6.3.5 Boston Scientific Drug-Coated Balloon 182

6.3.6 Coroflex DEBlue 183

6.3.7 Covidien Drug-Coated Balloon 185

6.3.8 Caliber Therapeutics DEB 187

6.3.9 Elixir Medical Corporation DCB 188

6.3.10 LifeTech Scientific Corporation DEB 188

6.3.11 Micell Technologies Drug-Coated Balloon 188

6.3.12 Drug-Coated Chocolate DEB 190

6.3.13 Passeo-18 Lux 192

6.3.14 Vascular Nanotransfer Technologies Drug-Coated Balloon 193

6.3.15 WOMBAT DCB 194

 

7 Clinical Trial Analysis 196

7.1 Overview 196

7.2 Clinical Trials to Watch 196

7.2.1 Drug-Eluting Balloons 196

7.2.2 Vascular Stents 209

 

8 Industry Overview 215

8.1 Procedure Trends 215

8.1.1 Factors Contributing to the Rise of Coronary and Peripheral Interventions 215

8.1.2 Coronary Artery Disease 215

8.1.3 Peripheral Artery Disease 217

8.2 Physician Decision-Making Process 219

8.3 Market Access 221

8.3.1 Regulatory Process 222

8.3.2 Adoption 224

8.3.3 Reimbursement Trends in the Asia-Pacific Region 227

8.4 Regulatory Issues/Recalls 230

8.4.1 Regulatory Issues 230

8.4.2 Product Recalls 231

8.5 Mergers and Acquisitions/Partnerships 231

8.5.1 Biosensors International and Eurocor 231

8.5.2 Boston Scientific Corporation and Guidant Corporation 232

8.5.3 Covidien and ev3, CV Ingenuity 232

8.5.4 C.R. Bard and Lutonix 233

8.5.5 Micell Technologies and Maxcor Lifescience 233

8.5.6 Medrad and Bayer 234

8.5.7 Medtronic and Invatec 234

 

9 Current and Future Players 235

9.1 Overview 235

9.2 Trends in Corporate Strategy 236

9.3 Company Profiles 239

9.3.1 Aachen Resonance 239

9.3.2 AnGes MG 240

9.3.3 AngioScore 242

9.3.4 AVIDAL Vascular 244

9.3.5 B. Braun 246

9.3.6 Biosensors International 248

9.3.7 Biotronik 250

9.3.8 Blue Medical 252

9.3.9 Boston Scientific Corporation 254

9.3.10 Caliber Therapeutics 256

9.3.11 Cardionovum 258

9.3.12 Concept Medical Research 260

9.3.13 Cook Medical 262

9.3.14 Covidien 264

9.3.15 C.R. Bard 266

9.3.16 Elixir Medical Corporation 268

9.3.17 Eurocor 270

9.3.18 LifeTech Scientific Corporation 272

9.3.19 Medtronic 274

9.3.20 Micell Technologies 276

9.3.21 Minvasys 277

9.3.22 TriReme Medical 279

9.3.23 Vascular Nanotransfer Technologies 281

 

10 Market Drivers, Opportunities, Barriers and Substitutes 283

10.1 Market Drivers 283

10.1.1 Rising Prevalence of Disease 284

10.1.2 Viable Treatment for Select Indications 285

10.1.3 No Metal Left Behind 290

10.1.4 Avoid Stent-in-Stent Procedures 291

10.1.5 Reduce the Need for Prolonged Dual Antiplatelet Therapy 292

10.1.6 Enhanced Vessel Healing and Better Patency 292

10.1.7 Technical Feasibility of Future Interventions 293

10.1.8 DEB as an Adjunctive Therapy 294

10.1.9 Limb Amputation 294

10.1.10 Cost Savings 295

10.1.11 Availability of Long-Term and Cost-Effective Data 296

10.1.12 Launch of DEB in the US 296

10.2 Opportunities 297

10.2.1 Improve DEB Design 297

10.2.2 DEB Hybrid Systems (DEB + Stent) 301

10.2.3 Target Indications Where Stenting is Not Satisfactory 302

10.2.4 Challenges in Treating the Femoropopliteal and Infrapopliteal Arteries 305

10.2.5 Target Challenging Patient Populations 306

10.2.6 Launch DEB in the Japanese Market 307

10.2.7 Emerging Markets 308

10.3 Market Barriers 308

10.3.1 Slow Adoption 308

10.3.2 High Selling Prices 312

10.3.3 Lack of Reimbursement 313

10.3.4 US FDA Regulatory Challenges 314

10.3.5 Healthcare Cost-Cutting and Reimbursement 315

10.3.6 Availability of Venture Capital 316

10.3.7 Medical Device Excise Tax 317

10.4 Market Substitutes 317

10.4.1 Vascular Stents 317

10.4.2 Liquid Drug Delivery Catheter 321

 

11 Drug-Eluting Balloon Market Analysis 324

11.1 APAC Market Overview 324

11.2 Market Analysis by Type of Disease 325

11.2.1 Coronary Artery Disease 325

11.2.2 Peripheral Artery Disease in the Lower Extremity 326

11.3 Market Distribution by Indication 328

11.4 Primary Versus Adjunctive Therapy 330

11.5 Comparative Market Analysis 332

11.5.1 Coronary Artery Disease 332

11.5.2 Peripheral Artery Disease in the Lower Extremity 334

 

12 Country Outlooks & Forecasts 336

12.1 Overview 336

12.2 Japan 337

12.2.1 Overview 337

12.2.2 Market Analysis 337

12.3 China 340

12.3.1 Overview 340

12.3.2 Market Analysis 340

12.4 India 343

12.4.1 Overview 343

12.4.2 Market Analysis 343

 

13 Appendix 346

13.1 Bibliography 346

13.2 Abbreviations 371

13.3 Report Methodology 375

13.3.1 Overview 375

13.3.2 Coverage 375

13.3.3 Secondary Research 375

13.3.4 Forecasting Methodology 376

13.4 Physicians and Specialists Included in this Study 378

13.5 Physician Survey 381

13.6 About the Authors 382

13.6.1 Analysts 382

13.6.2 Global Head of Healthcare 383

13.7 About MediPoint 384

13.8 About GlobalData 384

13.9 Disclaimer 384

 

List of Tables

 

Table 1: Classification Systems for Determining the Severity of PAD Symptoms 37

Table 2: Risk Factors Associated with CAD and PAD 38

Table 3: Types of Atherosclerotic Lesions 40

Table 4: Treatment Guidelines to Improve the Symptoms of CAD* 45

Table 5: TASC II Classification of Iliac Artery Lesions 47

Table 6: TASC II Classification of Femoropopliteal Artery Lesions 48

Table 7: TASC II Classification of Infrapopliteal Artery Lesions 49

Table 8: Types of Coronary Artery Bypass Grafting 60

Table 9: Complications of Coronary/Peripheral Artery Bypass Surgery 61

Table 10: Indications for Using Drug-Eluting Balloons 64

Table 11: Drug-Eluting Balloon Coating Characteristics 67

Table 12: Drugs Incorporated Into Drug-Eluting Stents 70

Table 13: Types of Lesions Treated Using Atherectomy 73

Table 14: Prevalence of CAD in the Population Age ?65 Years in the APAC Market (millions), 2010-2019 78

Table 15: Prevalence of PAD in the Population Age ?65 Years in the APAC Market (millions), 2010-2019 81

Table 16: Direct and Indirect Healthcare Costs 83

Table 17: APAC DEB Market ($m) for Treating Coronary and Peripheral Artery Disease, 2012 85

Table 18: Marketed DEB Products 87

Table 19: Elutax SV Product Portfolio 88

Table 20: Elutax SV SWOT Analysis, 2013 90

Table 21: SeQuent Please Product Portfolio 91

Table 22: SeQuent Please SWOT Analysis, 2013 96

Table 23: Pantera Lux Product Portfolio 97

Table 24: Pantera Lux SWOT Analysis, 2013 99

Table 25: Pioneer Product Portfolio 100

Table 26: Pioneer SWOT Analysis, 2013 102

Table 27: Protégé Product Portfolio 103

Table 28: Protégé SWOT Analysis, 2013 106

Table 29: Restore DEB Product Portfolio 107

Table 30: Restore DEB SWOT Analysis, 2013 108

Table 31: Legflow DEB Product Portfolio 109

Table 32: Legflow DEB SWOT Analysis, 2013 111

Table 33: Other DEB Products Developed by Cardionovum 112

Table 34: Lutonix Product Portfolio 113

Table 35: Lutonix SWOT Analysis, 2013 118

Table 36: Magic Touch Product Portfolio 119

Table 37: Magic Touch SWOT Analysis, 2013 121

Table 38: Advance 18 PTX Product Portfolio 122

Table 39: Advance 18 PTX SWOT Analysis, 2013 124

Table 40: Dior Product Portfolio 125

Table 41: Dior SWOT Analysis, 2013 131

Table 42: Freeway Family of DEB Product Portfolio 132

Table 43: Freeway Family of DEB SWOT Analysis, 2013 135

Table 44: Magical Product Portfolio 136

Table 45: Magical SWOT Analysis, 2013 138

Table 46: Cotavance Product Portfolio 139

Table 47: Cotavance SWOT Analysis, 2013 141

Table 48: IN.PACT Family DEB Product Portfolio 142

Table 49: IN.PACT SWOT Analysis, 2013 149

Table 50: Danubio Product Portfolio 150

Table 51: Danubio SWOT Analysis, 2013 151

Table 52: Global DEB Pipeline Products 174

Table 53: NF-?B Decoy Oligo DEB SWOT Analysis, 2013 177

Table 54: AngioSculpt SWOT Analysis, 2013 179

Table 55: BioPath SWOT Analysis, 2013 181

Table 56: BioStream SWOT Analysis, 2013 182

Table 57: Boston Scientific DEB SWOT Analysis, 2013 183

Table 58: Coroflex DEBlue SWOT Analysis, 2013 185

Table 59: Covidien DCB SWOT Analysis, 2013 187

Table 60: Micell Technologies' DCB SWOT Analysis, 2013 189

Table 61: Drug-Coated Chocolate DEB SWOT Analysis, 2013 191

Table 62: Passeo-18 Lux SWOT Analysis, 2013 193

Table 63: Vascular Nanotransfer Technologies DCB SWOT Analysis, 2013 194

Table 64: WOMBAT DCB SWOT Analysis, 2013 195

Table 65: Reimbursement Classification of Medical Devices in Japan 228

Table 66: Aachen Resonance Company Profile 239

Table 67: Aachen Resonance, Marketed DEB Product 240

Table 68: Aachen Resonance SWOT Analysis, 2013 240

Table 69: AnGes MG Company Profile 241

Table 70: AnGes MG, Pipeline DEB Product 242

Table 71: AnGes MG SWOT Analysis, 2013 242

Table 72: AngioScore Company Profile 243

Table 73: AngioScore, Pipeline DEB Product 243

Table 74: AngioScore SWOT Analysis, 2013 244

Table 75: AVIDAL Vascular Company Profile 244

Table 76: AVIDAL Vascular, Pipeline DEB Product 245

Table 77: AVIDAL Vascular SWOT Analysis, 2013 246

Table 78: B. Braun Company Profile 246

Table 79: B. Braun, Marketed and Pipeline DEB Products 247

Table 80: B. Braun SWOT Analysis, 2013 248

Table 81: Biosensors International Company Profile 249

Table 82: Biosensors International, Pipeline DEB Products 249

Table 83: Biosensors International SWOT Analysis, 2013 250

Table 84: Biotronik Company Profile 251

Table 85: Biotronik, Marketed and Pipeline DEB Products 251

Table 86: Biotronik SWOT Analysis, 2013 252

Table 87: Blue Medical Company Profile 253

Table 88: Blue Medical, Marketed DEB Products 254

Table 89: Blue Medical SWOT Analysis, 2013 254

Table 90: Boston Scientific Corporation Company Profile 255

Table 91: Boston Scientific Corporation, Pipeline DEB Product 255

Table 92: Boston Scientific Corporation SWOT Analysis, 2013 256

Table 93: Caliber Therapeutics Company Profile 256

Table 94: Caliber Therapeutics, Pipeline DEB Product 257

Table 95: Caliber Therapeutics SWOT Analysis, 2013 258

Table 96: Cardionovum Company Profile 258

Table 97: Cardionovum, Marketed and Pipeline DEB Products 259

Table 98: Cardionovum SWOT Analysis, 2013 260

Table 99: Concept Medical Research Company Profile 260

Table 100: Concept Medical Research, Marketed DEB Product 261

Table 101: Concept Medical Research SWOT Analysis, 2013 262

Table 102: Cook Medical Company Profile 262

Table 103: Cook Medical, Marketed DEB Product 263

Table 104: Cook Medical SWOT Analysis, 2013 264

Table 105: Covidien Company Profile 265

Table 106: Covidien, Pipeline DEB Product 265

Table 107: Covidien SWOT Analysis, 2013 266

Table 108: C.R. Bard Company Profile 266

Table 109: C.R. Bard, Marketed DEB Products 267

Table 110: C.R. Bard SWOT Analysis, 2013 268

Table 111: Elixir Medical Corporation Company Profile 268

Table 112: Elixir Medical Corporation, Pipeline DEB Product 269

Table 113: Elixir Medical Corporation SWOT Analysis, 2013 269

Table 114: Eurocor Company Profile 270

Table 115: Eurocor, Marketed DEB Products 271

Table 116: Eurocor SWOT Analysis, 2013 271

Table 117: LifeTech Scientific Corporation Company Profile 272

Table 118: LifeTech Scientific, Pipeline DEB Product 273

Table 119: LifeTech Scientific SWOT Analysis, 2013 273

Table 120: Medtronic Company Profile 274

Table 121: Medtronic, Marketed DEB Products 275

Table 122: Medtronic SWOT Analysis, 2013 275

Table 123: Micell Technologies Company Profile 276

Table 124: Micell Technologies, Pipeline DEB Product 277

Table 125: Micell Technologies SWOT Analysis, 2013 277

Table 126: Minvasys Company Profile 278

Table 127: Minvasys, Marketed DEB Product 278

Table 128: Minvasys SWOT Analysis, 2013 279

Table 129: TriReme Medical Company Profile 279

Table 130: TriReme Medical, Pipeline DEB Product 280

Table 131: TriReme Medical SWOT Analysis, 2013 280

Table 132: Vascular Nanotransfer Technologies Company Profile 281

Table 133: Vascular Nanotransfer Technologies, Pipeline DEB Product 282

Table 134: Vascular Nanotransfer Technologies SWOT Analysis, 2013 282

Table 135: APAC Coronary and Peripheral DEB Market ($m) Forecast, 2010-2019 325

Table 136: APAC DEB Market ($m) for Treating PAD in the Lower Extremity, 2010-2019 326

Table 137: Percent of Patients with CAD or PAD Receiving Stenting with DEB Angioplasty, APAC, 2012 and 2018 (N=33) 330

Table 138: DEB Sales ($m) Forecast for Japan, 2010-2019 338

Table 139: DEB Sales ($m) Forecast for China, 2010-2019 340

Table 140: DEB Sales ($m) Forecast for India, 2010-2019 343

Table 141: Physicians Surveyed, By Country 381

 

List of Figures

 

Figure 1: Coronary Arteries of the Human Heart 30

Figure 2: Peripheral Arteries of the Lower Extremity 31

Figure 3: Pathophysiology of Coronary Artery Disease 33

Figure 4: Pathophysiology of Peripheral Artery Disease 34

Figure 5: Treatment Modalities - Coronary Artery Disease 51

Figure 6: Percent of Patients with CAD Who Receive Each Therapy Option Only, APAC, 2012 and 2019 (N=16) 52

Figure 7: Treatment Modalities - Peripheral Artery Disease 53

Figure 8: Percent of Patients with PAD Who Receive Each Therapy Option Only, APAC, 2012 (N=17) 54

Figure 9: Percent of Patients with PAD Who Receive Each Therapy Option Only, APAC, 2012 (N=17) 54

Figure 10: Drug-Eluting Balloon 63

Figure 11: Types of Stents Used to Treat CAD and PAD 69

Figure 12: Bare Metal Stent 69

Figure 13: Drug-Eluting Stent 70

Figure 14: Covered Stents 71

Figure 15: Bioabsorbable Stent - Remedy 72

Figure 16: Types of Atherectomy 74

Figure 17: Prevalence of CAD in the Population Age ?65 Years in the APAC Market (millions), 2010-2019 78

Figure 18: Prevalence of PAD in the Population Age ?65 Years in the APAC Market (millions), 2010-2019 81

Figure 19: APAC DEB Market Share for Treating Peripheral Artery Disease in the Lower Extremity, 2012 86

Figure 20: Image of the Protégé DEB 104

Figure 21: Percent of CAD and PAD Patients with Acute Vessel Recoil After Standard Balloon Angioplasty, APAC, 2012 and 2018 (N=33) 159

Figure 22: Percent of CAD and PAD Patients with Thrombosis After Stenting, APAC, 2012 and 2018 (N=33) 161

Figure 23: Percent of CAD and PAD Patients with ISR, APAC, 2012 and 2018 (N=33) 162

Figure 24: Percent of CAD and PAD Patients Who Receive Stent-In-Stent Procedures, APAC, 2012 and 2018 (N=33) 163

Figure 25: Percent of CAD and PAD Patients with Stent Fracture, APAC, 2012 and 2018 (N=33) 166

Figure 26: Global DEB Pipeline Products by Stage of Development, 2013 173

Figure 27: AngioSculpt Scoring Balloon Expansion Profile 178

Figure 28: Drug-Coated Chocolate DEB 190

Figure 29: Population (? 65 years) of CAD Patients Receiving Interventional Procedures, APAC*, 2010-2019 216

Figure 30: Population (? 65 years) with PAD Receiving Interventional Procedures for the Peripheral Arteries in the Lower Extremity, APAC*, 2010-2019 217

Figure 31: Population (? 65 years) with PAD Receiving DEB Angioplasty for the Peripheral Arteries in the Lower Extremity, APAC*, 2010-2019 218

Figure 32: DEB Market for Treating CAD and PAD in the Lower Extremity, Company Share (%), 2012 235

Figure 33: DEB Market for Each Type of Disease, Company Share (%), 2012 237

Figure 34: Importance of Each Therapy Attribute in Adopting DEB for the Treatment of CAD and PAD, Global, 2012 (N=112) 298

Figure 35: APAC DEB Market ($m) for Treating Coronary Artery Disease and Peripheral Artery Disease in the Lower Extremity, 2010-2019 324

Figure 36: APAC DEB Market ($m) for Treating PAD in the Lower Extremity, 2010-2019 327

Figure 37: APAC DEB Market Share for Peripheral Artery Revascularization in the Lower Extremity , 2012 and 2019 328

Figure 38: APAC DEB Market Distribution (%) by Indication, 2012 and 2018 (N=33) 329

Figure 39: Percent of Patients with CAD Receiving Each Type of Interventional Technique Only, APAC, 2018 (N=16) 333

Figure 40: Percent of Patients with Lower Limb PAD Receiving Each Type of Interventional Technique Only, APAC, 2018 (N=17) 334

Figure 41: APAC DEB Market Revenue ($m), 2019 336

Figure 42: Japanese DEB Market ($m) for Coronary and Peripheral Applications, 2010-2019 338

Figure 43: Chinese DEB Market ($m) for Coronary and Peripheral Applications, 2010-2019 341

Figure 44: Indian DEB Market ($m) for Coronary and Peripheral Applications, 2010-2019 344